News | May 14, 2015

Antiplatelet Drug Ticagrelor More Effective Than Clopidogrel for Ad Hoc PCI Patients

New study finds ticagrelor works more quickly when given at the time of PCI

May 14, 2015 — A new study reports that antiplatelet drug ticagrelor (Brilinta) works faster and is more effective in blocking platelet activity in low-risk patients with acute coronary syndrome (ACS) than clopidogrel. The study was presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2015 Scientific Sessions in San Diego.

Ticagrelor was approved by the U.S. Food and Drug Administration (FDA) in 2011 based on results from the PLATO trial, which compared ticagrelor to clopidogrel in patients pre-treated with one of the medications plus aspirin prior to percutaneous coronary intervention (PCI). However, many low-risk ACS patients undergoing “ad hoc” PCI, or PCI following a diagnostic catheterization, are not pre-treated with an antiplatelet drug.

In the trial presented at SCAI, 100 patients were randomized to receive either ticagrelor (180 mg loading dose and 90 mg after 12 hours) or clopidogrel (600 mg loading dose) with aspirin (75-100 mg daily) at the time of PCI. All of the patients tested negative for troponin, a substance in the blood indicating damage to the heart muscle. Researchers measured platelet reactivity prior to receiving the medication; at 0.50, two-and eight-hour intervals; and at the end of PCI. The primary endpoint of the study was platelet reactivity at two hours.

The study found platelet activity differed as early as one-half hour after the medication was administered. Significant reduction in platelet activity began as early as the end of PCI, which occurred a mean 0.6 hours after the medication was given, and continued to decrease at eight hours.

“At standard doses, ticagrelor works faster and better inhibits platelet activity than clopidogrel in low-risk ACS patients,” said Roxana Mehran, M.D., FSCAI, director of cardiovascular research and interventional clinical trials at Mount Sinai Medical Center in New York, and the study’s principal investigator. “The study suggests low-risk patients undergoing ad hoc PCI may fare better with ticagrelor.”

Mehran has received research grants from DSI/Eli Lilly, Bristol-Myers Squibb/Sanofi-Aventis, AstraZeneca, and The Medicines Company; and consulting or advisory board fees from AstraZeneca, Bayer, CSL Behring, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Osprey Medical Inc., Regado Biosciences, Inc., The Medicines Company, Watermark Consulting, Abbott Laboratories, Boston Scientific, Covidien, and Sanofi-Aventis.

For more information: www.scai.org

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init